|
The pharmacological properties of IDX19368, a novel nucleotide prodrug, highlight its potential for use in a low-dose DAA regimen for HCV
|
|
|
Reported by Jules Levin
Presented at the 19th International Symposium on Hepatitis C Virus and Related Viruses; Venice, Italy; October 5-9, 2012
J. P. Bilello, C. B. Dousson, C. Pierra, D. Surleraux, M. La Colla, C. Chapron, I. Serra, N. Golitsina, F. Danehy, M. Camire, B. Hernandez-Santiago, J. F. McCarville, S. Bhadresa, X.R. Pan-Zhou, L. B. Lallos, H. Rashidzadeh, K. Gupta, M. Seifer, R. Rush and D. N. Standring
Idenix Pharmaceuticals, Inc., Cambridge, MA, USA and Montpellier, France.
![HCV1.gif](../images/020113/020113-4/HCV1.gif)
![HCV2.gif](../images/020113/020113-4/HCV2.gif)
![HCV3.gif](../images/020113/020113-4/HCV3.gif)
![HCV4.gif](../images/020113/020113-4/HCV4.gif)
![HCV5.gif](../images/020113/020113-4/HCV5.gif)
![HCV6.gif](../images/020113/020113-4/HCV6.gif)
![HCV7.gif](../images/020113/020113-4/HCV7.gif)
![HCV8.gif](../images/020113/020113-4/HCV8.gif)
|
|
|
|
|
|
|